GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
IM-MV 19-024_000 Stichting Katholieke Universiteit EXPLORE: A Phase II, masked multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration 16-04-2020 Vergunning verleend
IM-MV 20-001_000 UMCG Clinical testing of TX200-TR101, an autologous antigen-specific chimeric antigen receptor (CAR) T regulatory cell therapy. 12-05-2020 Vergunning verleend
IM-MV 20-002_000 Het Nederlands Kanker Instituut Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies Ontwerpbesluit genomen
IM-MV 20-003_000 AMC Clinical studies with MB‐CART2019.1, a product consisting of ex‐vivo lentiviral transduced T‐cells using a replication‐deficient lentiviral vector Ontwerpbesluit genomen
IM-MV 20-004_000 UMCG Clinical studies with MB-CART2019.1, a product consisting of ex-vivo lentiviral transduced T-cells using a replication-deficient lentiviral vector Ontwerpbesluit genomen
IM-MV 20-005_000 Erasmus MC Use of autologous patient-derived T cells enriched from peripheral blood mononuclear cells (PBMCs) and transduced with a gamma-retroviral self-inactivating (SIN) vector expressing a second generation chimeric antigen receptor (CAR) with specificity for the oncofetal antigen Claudin6 (CLDN6) under control of an internal promoter in patients suffering from CLDN6-positive malignancies Ontwerpbesluit genomen